Remodulin (treprostinil sodium)
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Mar 1, 2005 → Oct 1, 2005
NCT ID
NCT00494533About Remodulin (treprostinil sodium)
Remodulin (treprostinil sodium) is a approved stage product being developed by United Therapeutics for Pulmonary Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT00494533. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00494533 | Approved | Terminated |
Competing Products
20 competing products in Pulmonary Arterial Hypertension